Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 3/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenanthridine SCHEMBL9106884 | 0.98 | GPR3 (1.00) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL30914262 | 0.98 | GPR3 (1.00) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL30823553 | 0.98 | GPR3 (1.00) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL8666 | 0.98 | GPR3 (1.00) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL2422346 | 0.95 | GPR3 (0.95) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL460289 | 0.95 | GPR3 (0.95) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL3702845 | 0.95 | GPR3 (0.95) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL2421052 | 0.95 | GPR3 (0.95) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL8505090 | 0.95 | GPR3 (0.95) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL29754194 | 0.95 | GPR3 (0.95) | GPR3KDM4ECYP3A4TOP2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118370839-A | Surface charge inversion type amphiphilic platinum prodrug nano-particle and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-118370839-A | Surface charge inversion type amphiphilic platinum prodrug nano-particle and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-114569734-B | Preparation method of nanoparticle for delivering cationic platinum drug based on reduction-sensitive polymer | 北京化工大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-114569734-B | Preparation method of nanoparticle for delivering cationic platinum drug based on reduction-sensitive polymer | 北京化工大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-114569734-A | Preparation method of nanoparticles for delivering cationic platinum drug based on reduction sensitive polymer | 北京化工大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-114569734-A | Preparation method of nanoparticles for delivering cationic platinum drug based on reduction sensitive polymer | 北京化工大学 | 2022-06-03 | — | — | CN | disclosed |
| US-11304958-B2 | Multidentate phenanthridine-containing ligand frameworks and their planar monofunctional platinum complexes for cancer treatment | UNIVERSITY OF MANITOBA (CA) | 2022-04-19 | — | — | US | disclosed |
| US-20210052601-A1 | Multidentate Phenanthridine-Containing Ligand Frameworks and Their Planar Monofunctional Platinum Complexes for Cancer Treatment | UNIVERSITY OF MANITOBA (CA) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304958-B2 | Multidentate phenanthridine-containing ligand frameworks and their planar monofunctional platinum complexes for cancer treatment | PDCD1, BID, PDCD1LG2 | GPR3 1219/4885KDM4E 1839/4885CYP3A4 87/4885 |
| US-20210052601-A1 | Multidentate Phenanthridine-Containing Ligand Frameworks and Their Planar Monofunctional Platinum Complexes for Cancer Treatment | PDCD1, BID, PDCD1LG2 | GPR3 1219/4885KDM4E 1839/4885CYP3A4 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.